Submit Deal

Announced

10 Aug 2017

Completed

16 Aug 2018

Bain Capital, and Cinven, to make an offer for the 63% of STADA Arzneimittel AG's shares.

Synopsis

Bain Capital, private equity firm, and Cinven, private equity firm, acquired 63% of the outstanding shares of the German generic drugmaker STADA Arzneimittel.

Principals

target

Stada Arzneimittel

bidder

Bain Capital

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (12)

mark keatley

CFO at STADA ARZNEIMITTEL AG

Manager

target

Deals

£ 4.45 B

Total Value

peter goldschmidt

Chairman and CEO at STADA ARZNEIMITTEL AG

Manager

target

Deals

£ 4.96 B

Total Value

nadine kari

Skadden Arps Slate Meagher & Flom

Lawyer

target

Deal

£ 2.89 B

Total Value

tobias pukropski

Principal Associate at Freshfields Bruckhaus Deringer

Lawyer

target

Deals

£ 34.45 B

Total Value

michael albrecht

Skadden Arps Slate Meagher & Flom

Lawyer

target

Deals

£ 2.96 B

Total Value

vera barthel-westphal

Freshfields Bruckhaus Deringer

Lawyer

target

Deals

£ 3.06 B

Total Value

georg guntrum

Freshfields Bruckhaus Deringer

Lawyer

target

Deal

£ 2.89 B

Total Value

katrin gassner

Partner at Freshfields Bruckhaus Deringer

Lawyer

target

Deals

£ 46.54 B

Total Value

miguel pagan fernandez

Chief Technology Officer at STADA ARZNEIMITTEL AG

Manager

target

Deals

£ 4.45 B

Total Value

bernd mayer

Skadden Arps Slate Meagher & Flom

Lawyer

target

Deal

£ 2.89 B

Total Value

damien simonot

Skadden Arps Slate Meagher & Flom

Lawyer

target

Deals

£ 4.50 B

Total Value

philip heske

Skadden Arps Slate Meagher & Flom

Lawyer

target

Deals

£ 3.79 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy